Aptevo Therapeutics Stock Performance
| APVO Stock | USD 9.20 0.47 5.38% |
Aptevo Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Aptevo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aptevo Therapeutics is expected to be smaller as well. Aptevo Therapeutics right now shows a risk of 12.65%. Please confirm Aptevo Therapeutics skewness, and the relationship between the value at risk and day median price , to decide if Aptevo Therapeutics will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Aptevo Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Aptevo Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Actual Historical Performance (%)
One Day Return 5.38 | Five Day Return (6.50) | Year To Date Return (96.83) | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:37 | Dividend Date 2020-03-27 | Last Split Date 2024-12-04 |
1 | Aptevo Therapeutics Now Covered by Analysts at StockNews.com | 10/10/2024 |
2 | Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Type... | 10/29/2024 |
3 | Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB | 10/31/2024 |
4 | Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update | 11/07/2024 |
5 | Armistice Capital, LLCs Strategic Acquisition of Aptevo Therapeutics Inc Shares | 11/15/2024 |
6 | First Patient Dosed in Aptevos Ongoing RAINIER Trial Achieves 90 percent Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall E... | 11/20/2024 |
7 | Aptevo Highlights the Potential of the Companys Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance... | 11/22/2024 |
8 | Proving the Concept Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation | 11/26/2024 |
9 | Aptevo Therapeutics announces 1-for-37 reverse stock split APVO | 11/29/2024 |
10 | Aptevo Therapeutics executes reverse stock split | 12/04/2024 |
| Begin Period Cash Flow | 22.6 M |
Aptevo |
Aptevo Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,333 in Aptevo Therapeutics on September 12, 2024 and sell it today you would lose (413.00) from holding Aptevo Therapeutics or give up 30.98% of portfolio value over 90 days. Aptevo Therapeutics is currently generating 0.1876% in daily expected returns and assumes 12.6465% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Aptevo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aptevo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aptevo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aptevo Therapeutics, and traders can use it to determine the average amount a Aptevo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0148
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | APVO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.65 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Aptevo Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aptevo Therapeutics by adding it to a well-diversified portfolio.
Aptevo Therapeutics Fundamentals Growth
Aptevo Stock prices reflect investors' perceptions of the future prospects and financial health of Aptevo Therapeutics, and Aptevo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aptevo Stock performance.
| Return On Equity | -2.51 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 1.93 M | ||||
| Shares Outstanding | 500.33 K | ||||
| Price To Earning | 2.48 X | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 1.61 X | ||||
| Gross Profit | 3.11 M | ||||
| EBITDA | (28.31 M) | ||||
| Net Income | (17.41 M) | ||||
| Cash And Equivalents | 29.43 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 5.4 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | 0.26 X | ||||
| Cash Flow From Operations | (11.73 M) | ||||
| Earnings Per Share | (415.99) X | ||||
| Market Capitalization | 4.37 M | ||||
| Total Asset | 24.84 M | ||||
| Retained Earnings | (223.45 M) | ||||
| Working Capital | 11.84 M | ||||
| Current Asset | 71.41 M | ||||
| Current Liabilities | 19.54 M | ||||
About Aptevo Therapeutics Performance
By examining Aptevo Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Aptevo Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Aptevo Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 731.88 | 768.48 | |
| Return On Tangible Assets | (0.70) | (0.74) | |
| Return On Capital Employed | (1.64) | (1.72) | |
| Return On Assets | (0.70) | (0.67) | |
| Return On Equity | (1.42) | (1.50) |
Things to note about Aptevo Therapeutics performance evaluation
Checking the ongoing alerts about Aptevo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aptevo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aptevo Therapeutics had very high historical volatility over the last 90 days | |
| Aptevo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Aptevo Therapeuticshas 734,635 shares shorted by Aptevo Therapeutics investors is about 100% of outstending shares | |
| Net Loss for the year was (17.41 M) with profit before overhead, payroll, taxes, and interest of 3.11 M. | |
| Aptevo Therapeutics currently holds about 29.43 M in cash with (11.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. | |
| Latest headline from investing.com: Aptevo Therapeutics executes reverse stock split |
- Analyzing Aptevo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aptevo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aptevo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aptevo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aptevo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aptevo Therapeutics' stock. These opinions can provide insight into Aptevo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (415.99) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.